systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-184Research ArticleСТАТЬИARTICLESМесто b-блокаторов и диуретиков в Российских рекомендациях по артериальной гипертонии 2008 года.The place of b-blocker and diuretic in the Russian guidelines of arterial hypertension 2008ЧазоваИ. Е.noemail@neicon.ruРатоваЛ. Г.noemail@neicon.ruChazovaI. E.noemail@neicon.ruRatovaL. G.noemail@neicon.ruФГУ РКНПК Федерального агентства по высокотехнологичной медицинской помощи, МоскваRussian Federation20092312202261411Copyright © Чазова И.Е., Ратова Л.Г., Chazova I.E., Ratova L.G., 20222022Чазова И.Е., Ратова Л.Г., Chazova I.E., Ratova L.G.Чазова И.Е., Ратова Л.Г., Chazova I.E., Ratova L.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/184артериальная гипертензияb-блокаторыReferencesДиагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. Прил. 2. 2008; 7 (6).Диагностика и лечение артериальной гипертензии. Российские рекомендации. Кардиоваск. тер. и проф. Прил. 2. 2008; 7 (6).ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105-87.Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25: 1341-62.Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the swidish trial in old patients with hypertension (STOP-Hypertension). Lancet 19991; 338: 1281-5.Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the swidish trial in old patients with hypertension (STOP-Hypertension). Lancet 19991; 338: 1281-5.Olsson G, Tuomilehto J, Berglund G et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151-8.Olsson G, Tuomilehto J, Berglund G et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991; 4: 151-8.Wiysonge CS, Bradley H, Mayosi BM et al. Beta blockers for hypertension. Cochrane Database Review 2007; 1: CD002003.Wiysonge CS, Bradley H, Mayosi BM et al. Beta blockers for hypertension. Cochrane Database Review 2007; 1: CD002003.Egstrup et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33.Egstrup et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33.Остроумова О.Д., Рыкова А.М. и др. Выбор антигипертензивных препаратов у больных с сочетанием артериальной гипертензии и ишемической болезни сердца: фокус на b-блокаторы. Consilium Medicum 2007; 9 (5).Остроумова О.Д., Рыкова А.М. и др. Выбор антигипертензивных препаратов у больных с сочетанием артериальной гипертензии и ишемической болезни сердца: фокус на b-блокаторы. Consilium Medicum 2007; 9 (5).Frishman WH. Postinfarction survival: role of beta-adrenic blocade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippencott 1996: 1205-14.Frishman WH. Postinfarction survival: role of beta-adrenic blocade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia, Lippencott 1996: 1205-14.Omvik P et al. Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65-73.Omvik P et al. Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65-73.Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-7.Wiklund O, Hulthe J, Wikstrand J et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-7.Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Clin Med J 1995; 108 (9): 710-7.Post-stroke antihypertensive treatment study. A preliminary result. PATS Collaborating Group. Clin Med J 1995; 108 (9): 710-7.Beckett NS, Peters R, Fletcher AE et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358 (18): 1887-98.Beckett NS, Peters R, Fletcher AE et al. The HYVET Study Group. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358 (18): 1887-98.Gueyffier F, Bulpitt C, Boissel JP et al.; the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353 (9155): 793-6.Gueyffier F, Bulpitt C, Boissel JP et al.; the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 1999; 353 (9155): 793-6.Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144 (12): 884-93.Messerli FH, Mancia G, Conti CR et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144 (12): 884-93.
The authors declare that there are no conflicts of interest present.